Privi Speciality Chemicals Ltd
PRIVISCLPrivi Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew +75.1% in a year against a +50.0% price move.
The sharpest disagreement: annual EPS moved +75.1% against a +50.0% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (65 weeks in) while the P/E sits at the 53rd percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +46.9% year on year, and 198% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Privi Speciality Chemicals Ltd trades at ₹3,677, in a confirmed uptrend and 65 weeks into that stage. That is +21.0% against its own 200-day average. It sits at 99% of a 52-week range of ₹2,283 to ₹3,695. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 65 of stage 2, confirmed. At ₹3,677 it trades +21.0% versus its 200-day average and sits at 99% of its 52-week range (₹2,283–₹3,695).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +1,595% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 53rd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Privi Speciality Chemicals Ltd trades at 42.9× P/E, mid-range by its own standards (53rd percentile). Its long-run median P/E is 41.0×, measured across 9.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 42.9× is mid-range by its own standards (53rd percentile), against a long-run median of 41.0× measured over 9.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +75.1% against a +50.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +21.9%/yr price move, ~+26.8%/yr came from earnings growth and ~−4.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Privi Speciality Chemicals Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 22.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +22.0% | +16.8% | +15.0% | — |
| Profit | +71.4% | +147.1% | +22.1% | — |
| EPS | +75.1% | +145.2% | +22.9% | — |
| Share price | +50.0% | +50.1% | +21.9% | +28.5% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
66.2/100 — rank 2 of 27 in Speciality Chemicals · 72% evidence confidence
Privi Speciality Chemicals Ltd scores 66.2 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 27.2 + 15.5 + 9.3 + 14.2 = 66.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Privi Speciality Chemicals Ltd reported ₹722 Cr of revenue in the Mar 26 quarter, +17.6% year on year. That is the 9th straight quarter of year-on-year growth. Over 9 years it has compounded at 17.6% a year. The last full year, FY26, came in at ₹2,564 Cr. The last four reported quarters add to ₹2,565 Cr.
Privi Speciality Chemicals Ltd reported ₹722 Cr of revenue in the Mar 26 quarter, +17.6% year on year. That is the 9th straight quarter of year-on-year growth. Over 9 years it has compounded at 17.6% a year. The last full year, FY26, came in at ₹2,564 Cr. The last four reported quarters add to ₹2,565 Cr.
FY26 revenue came in at ₹2,564 Cr (+22.0% on the year), capping 9 years at 17.6% compound. The latest quarter (Mar 26) printed ₹722 Cr, +17.6% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +22.2% growth against the decade's 17.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +22.0% over the last 4 quarters against +21.0%/yr over the last 8 — stabilising; TTM profit +72.3% vs +81.7%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 25.0% this quarter (+3.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Privi Speciality Chemicals Ltd's operating margin is 25.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 12.0% to 25.0%. The current quarter sits inside that band.
Privi Speciality Chemicals Ltd's operating margin is 25.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 12.0% to 25.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 25.0%, +3.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 12.0%–25.0%, and FY26's 25.0% is the top of that band — a record year.
Why the margin moved: operating margin went +3.4 pp year on year while gross margin went −0.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +46.9% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Privi Speciality Chemicals Ltd earned ₹94.0 Cr of net profit in the Mar 26 quarter, +46.9% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹317 Cr. The 9-year compound rate is 31.5%. That is 13.0% of the quarter's revenue. The same quarter a year earlier earned ₹64.0 Cr.
Privi Speciality Chemicals Ltd earned ₹94.0 Cr of net profit in the Mar 26 quarter, +46.9% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹317 Cr. The 9-year compound rate is 31.5%. That is 13.0% of the quarter's revenue. The same quarter a year earlier earned ₹64.0 Cr.
Mar 26 profit was ₹94.0 Cr, +46.9% year on year — the 8th consecutive quarter of growth. On the full year, FY26 printed ₹317 Cr (+71.4%), and the 9-year compound rate is 31.5%.
Why profit moved: revenue contributed +17.6% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +76.1% vs revenue +22.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 198% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 198% of Privi Speciality Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹550 Cr of operating cash against ₹317 Cr of profit. After ₹330 Cr of capital spending, ₹220 Cr was left as free cash.
FY26: operating cash of ₹550 Cr against reported profit of ₹317 Cr, leaving free cash of ₹220 Cr after ₹330 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 198% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 198%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹765 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Privi Speciality Chemicals Ltd's cash conversion cycle runs 160 days in FY26, up from 155 days in FY21. Capital spending ran ₹765 Cr over the last 3 years. At FY26 sales of ₹2,564 Cr each day of that cycle holds about ₹7.0 Cr, so roughly ₹1,124 Cr sits inside the business at any moment.
FY26: debtors at 75 days, inventory at 235 days — roughly 7.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 160 days, looser than FY21's 155.
The full loop: cash goes out to suppliers and production on day 0; stock waits 235 days to sell; customers pay about 75 days after that; and suppliers themselves are paid at 150 days — netting out to the 160-day cycle.
In money terms: at FY26 sales of ₹2,564 Cr, each day of the cycle holds about ₹7.0 Cr — so the 160-day loop keeps roughly ₹1,124 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹765 Cr over the last 3 fiscal years against ₹399 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹314 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 22%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Privi Speciality Chemicals Ltd earns a ROCE of 22% in FY26. That is up from a trough of 6% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.4% net margin on 0.81× asset turns.
FY26 ROCE is 22%, recovered from a FY23 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.4% net margin × 0.81× asset turns × 2.25× balance-sheet leverage ≈ 22.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.72.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Privi Speciality Chemicals Ltd carries ₹1,021 Cr of borrowings against ₹1,412 Cr of equity in FY26, a debt-to-equity of 0.72. Operating profit covers the interest bill 8×. Over 5 years borrowings went from ₹537 Cr to ₹1,021 Cr. Capital spending ran ₹765 Cr across the last 3 of those years.
FY26: borrowings of ₹1,021 Cr against equity of ₹1,412 Cr — a debt-to-equity of 0.72. Operating profit covers the interest bill 8×. Over 5 years borrowings went from ₹537 Cr to ₹1,021 Cr while capital spending ran ₹765 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.9% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 13.4 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 13.4 points of Privi Speciality Chemicals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.6% of the company. Domestic institutions moved +7.2 points over the same window, to 10.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −13.4 points over 8 quarters to 60.6%; Domestic institutions: +7.2 points over 8 quarters to 10.1%; Foreign institutions: +1.5 points over 8 quarters to 1.9%.
🚨 Why the register moved: promoters drove it (−13.4 points), absorbed on the other side by domestic institutions (+7.2 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Privi Speciality Chemicals Ltd: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
The safety line in one sentence: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Privi Speciality Chemicals Ltd this page | 42.9× | ₹14,044 Cr | Mixed | |||
| Pidilite Industries Ltd | 64.9× | ₹1.6L Cr | Consistent | |||
| Aether Industries Ltd | 83.7× | ₹18,945 Cr | Mixed | |||
| Aarti Industries Ltd | 42.1× | ₹17,331 Cr | Turning around | |||
| Anupam Rasayan India Ltd | 83.6× | ₹14,226 Cr | Improving | |||
| Vinati Organics Ltd | 30.4× | ₹13,478 Cr | Topping out | |||
| Alkyl Amines Chemicals Ltd | 48.3× | ₹9,153 Cr | No read | |||
| Clean Science & Technology Ltd | 33.4× | ₹7,663 Cr | Deteriorating | |||
| Galaxy Surfactants Ltd | 24.8× | ₹6,896 Cr | Mixed | |||
| Neogen Chemicals Ltd | 159.0× | ₹5,648 Cr | Mixed | |||
| Fineotex Chemical Ltd | 37.7× | ₹4,610 Cr | Turning around | |||
| Vishnu Chemicals Ltd | 29.9× | ₹4,257 Cr | Mixed | |||
| Tatva Chintan Pharma Chem Ltd | 76.9× | ₹4,029 Cr | Turning around | |||
| Yasho Industries Ltd | 147.0× | ₹3,704 Cr | Improving | |||
| Grauer & Weil (India) Ltd | 20.4× | ₹3,354 Cr | Turning around | |||
| Panama Petrochem Ltd | 14.2× | ₹3,014 Cr | Turning around | |||
| Fineotex Chemical Ltd | 28.3× | ₹2,551 Cr | Turning around | |||
| Thirumalai Chemicals Ltd | — | ₹2,022 Cr | No read | |||
| Paushak Ltd | 41.6× | ₹1,387 Cr | Mixed | |||
| Platinum Industries Ltd | 23.9× | ₹1,251 Cr | Improving | |||
| Amines & Plasticizers Ltd | 29.3× | ₹1,069 Cr | Topping out | |||
| Sunshield Chemicals Ltd | 35.5× | ₹1,051 Cr | Turning around | |||
| Vikram Thermo (India) Ltd | 20.0× | ₹768 Cr | Mixed | |||
| Sunshield Chemicals Ltd | 29.2× | ₹720 Cr | Turning around | |||
| DMCC Speciality Chemicals Ltd | 24.9× | ₹680 Cr | Mixed | |||
| Chemcon Speciality Chemicals Ltd | 27.4× | ₹647 Cr | Improving | |||
| Amal Ltd | 23.0× | ₹628 Cr | No read | |||
| Transpek Industry Ltd | 13.0× | ₹595 Cr | Deteriorating | |||
| Kronox Lab Sciences Ltd | 20.7× | ₹573 Cr | Mixed |
Frequently asked questions
What is Privi Speciality Chemicals Ltd's share price today?
Privi Speciality Chemicals Ltd trades at ₹3,677, +50.0% over the past year. The company is valued at ₹14,044 Cr. The stock sits at 99% of its 52-week range of ₹2,283–₹3,695, +21.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 65 weeks in. — as of 24 July 2026.
What were Privi Speciality Chemicals Ltd's latest quarterly results?
Privi Speciality Chemicals Ltd reported revenue of ₹722 Cr and net profit of ₹94.0 Cr for the Mar 26 quarter. Revenue rose 17.6% and profit rose 46.9% year on year. Earnings per share were ₹23.96. The operating margin was 25.0%, 3.0 pp higher than a year earlier. — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's revenue?
Privi Speciality Chemicals Ltd reported revenue of ₹722 Cr in the Mar 26 quarter, +17.6% year on year. For the full FY26 fiscal year, revenue was ₹2,564 Cr (+22.0%). Over the last 9 years revenue compounded at 17.6% a year. — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's profit?
Privi Speciality Chemicals Ltd earned ₹94.0 Cr of net profit in the Mar 26 quarter, +46.9% year on year — the 8th straight quarter of growth. Full-year FY26 profit was ₹317 Cr. The operating margin ran 25.0% in the latest quarter. — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's market cap?
Privi Speciality Chemicals Ltd's market capitalisation is ₹14,044 Cr at a share price of ₹3,677. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's P/E ratio?
Privi Speciality Chemicals Ltd trades at a P/E of 42.9×, at the 53rd percentile of its own 9-year range, against a long-run median of 41.0×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Privi Speciality Chemicals Ltd pay a dividend?
Yes — Privi Speciality Chemicals Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 9 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd overvalued?
On its own history, Privi Speciality Chemicals Ltd looks mid-range against its own history: its P/E of 42.9× sits at the 53rd percentile of its 9-year range (long-run median 41.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd growing?
Yes — Privi Speciality Chemicals Ltd is growing: latest-quarter revenue +17.6% year on year, profit +46.9%, and the margin +3.0 pp at 25.0%. The 9-year compound rates are 17.6% (revenue) and 31.5% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Privi Speciality Chemicals Ltd performing?
Privi Speciality Chemicals Ltd is in a confirmed uptrend, 65 weeks in. Its latest quarter's revenue rose 17.6% and profit rose 46.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Privi Speciality Chemicals Ltd in?
Mixed — no clean majority across the growth curves, ROCE lifting at 22.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +17.6% latest, profit growth +46.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 65 of stage 2), trading +21.0% versus its 200-day average and at 99% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd beating the market?
On recent form, yes — Privi Speciality Chemicals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +1,595% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will Privi Speciality Chemicals Ltd's share price go up?
This page publishes no price forecast for Privi Speciality Chemicals Ltd. What it measures instead: the share price is ₹3,677, the price is in a confirmed uptrend 65 weeks in. Its P/E of 42.9× sits at the 53rd percentile of its own 9-year range. — as of 24 July 2026.
Who owns Privi Speciality Chemicals Ltd?
Promoters hold 60.6% of Privi Speciality Chemicals Ltd, foreign institutions 1.9%, domestic institutions 10.1% and the public 27.4% (latest quarter). The biggest move on the register over the last two years: Promoters cut 13.4 points over 8 quarters. — as of 24 July 2026.
Does Privi Speciality Chemicals Ltd have too much debt?
It is moderate — Privi Speciality Chemicals Ltd's debt-to-equity is 0.72, and operating profit covers the interest bill 8×. FY26 borrowings were ₹1,021 Cr against equity of ₹1,412 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's capex?
Privi Speciality Chemicals Ltd spent ₹765 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹330 Cr, with ₹314 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Privi Speciality Chemicals Ltd's cash flow?
Privi Speciality Chemicals Ltd generated ₹550 Cr of operating cash flow in FY26 and ₹220 Cr of free cash flow after ₹330 Cr of capital spending. Reported profit that year was ₹317 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 198% of Privi Speciality Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹550 Cr against reported profit of ₹317 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Privi Speciality Chemicals Ltd in its business cycle?
Privi Speciality Chemicals Ltd's FY26 operating margin was 25.0%, against a 10-year band of 12.0%–25.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Privi Speciality Chemicals Ltd story?
The sharpest disagreement: annual EPS moved +75.1% against a +50.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Privi Speciality Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Privi Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew +75.1% in a year against a +50.0% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.